And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
作者信息
Lau Sally C M, Ou Sai-Hong Ignatius
机构信息
Department of Oncology, Laura & Issac Perlmutter Cancer Center, NYU Langone Health, NYU Grossman School of Medicine, New York, New York.
Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.
出版信息
J Thorac Oncol. 2022 Oct;17(10):1144-1154. doi: 10.1016/j.jtho.2022.08.016.
PMID:36192074
Abstract
摘要
Zotero 插件